Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Antimicrob Chemother ; 77(6): 1741-1747, 2022 05 29.
Article in English | MEDLINE | ID: mdl-35289854

ABSTRACT

BACKGROUND: Fast initiation of ART has been associated with higher rates of retention in HIV care and viral suppression at 48 weeks and with lower mortality rates. However, scarce evidence exists in our setting, where diagnosis and treatment are carried out in different contexts. METHODS: An observational retrospective study evaluating efficacy and safety of ART prescribed at the first specialist appointment, without baseline laboratory data, in a tertiary hospital in downtown Madrid. Individuals with a new diagnosis of HIV infection who initiated treatment at their first appointment with an infectious diseases specialist before receiving baseline laboratory results were included, irrespective of the ART regimen chosen. RESULTS: One hundred and eight participants were included. The majority (99.1%) were MSM who had acquired infection during sexual intercourse. The efficacy of ART, without baseline laboratory results at the time of initiation, was 85.2% (92/108) in the ITT analysis and 91.7% (99/108) in the treatment-related discontinuation equals failure analysis. All but nine patients presented an undetectable viral load (<50 copies/mL) at 48 weeks from starting ART. No serious adverse effects associated with the strategy were observed. In total, 101 participants continued care at 48 weeks with retention in HIV care rate of 93.5% (101/108). CONCLUSIONS: Initiating ART at the first available opportunity without baseline laboratory data does not reduce efficacy or safety of ART and achieves rapid virological control with high rates of retention in HIV care.


Subject(s)
Anti-HIV Agents , Drug-Related Side Effects and Adverse Reactions , HIV Infections , Adult , Anti-HIV Agents/adverse effects , CD4 Lymphocyte Count , Cognition , HIV Infections/drug therapy , Humans , Retrospective Studies , Viral Load
2.
Int J Infect Dis ; 115: 106-108, 2022 Feb.
Article in English | MEDLINE | ID: mdl-34838958

ABSTRACT

Sweet Syndrome belongs to a group of diseases known as neutrophilic dermatoses. An uncommon variant named Histiocytoid Sweet Syndrome (HSS) can be associated with a variety of conditions, including cancer, infections, drug toxicity and others. Here we present an instance of HSS in an HIV-positive patient in an infectious disease setting.


Subject(s)
HIV Infections , Lymphogranuloma Venereum , Sweet Syndrome , Chlamydia trachomatis , HIV Infections/complications , Homosexuality, Male , Humans , Lymphogranuloma Venereum/complications , Lymphogranuloma Venereum/diagnosis , Lymphogranuloma Venereum/drug therapy , Male , Sweet Syndrome/complications , Sweet Syndrome/diagnosis , Sweet Syndrome/drug therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...